International Journal of Clinical Research

Objective: To investigate the efficacy of adalimumab in the treatment of severe plaque psoriasis. Methods: According to the year 2021-04 to 2022-04, 76 patients with severe plaque psoriasis who were admitted to our hospital were randomly selected for research, and the patients were divided into groups by digital lottery method, and the control group There were 38 patients who received conventional western medicine treatment, and 38 patients in the other observation group were also treated with adalimumab. The clinical efficacy, skin conditions and adverse reactions of the two groups of patients were compared and analyzed. Results: By evaluating the adverse reactions of the two groups of patients, the incidence of fever, upper respiratory infection and dry skin in the observation group was lower than that in the control group (P<0.05). Conclusion: For the treatment of patients with severe plaque psoriasis, the clinical application of adalimumab has definite curative effect and high safety.

Adalimumab; Severe Plaque Psoriasis; Efficacy